|
|
 |
|
Viewing report
|
|
|
|
China Pharmaceutical Chain Industry Report, 2007-2008
Research In China, July 2008, Pages: 75
The pharmaceutical industry is called the ''eternal sunrise industry'', mainly because of its sustained growth in market demand. The main factors driving this growth include economic growth, improved public awareness of healthcare, the aging population, urbanization and health system reform, which has greatly promoted the ability and willingness of medical consumption. According to the forecasts of IMS, China will become the seventh largest pharmaceutical market in the world in 2009 and will jump to the second largest one with a market capacity of US$220 billion after the U.S.A. in 2020.
According to the latest statistics of the National Bureau of Statistics, the sales revenue of China's pharmaceutical industry in the first five months of this year reached CNY271.78 billion, up 26.63% year on year. In 2007, sales revenue reached CNY575.4 billion, rising 21.5% year on year. The average growth rate of sales revenue of China's pharmaceutical industry in the past ten years exceeded 20%, far higher than GDP growth rate in the same period. Moreover, the profit growth rate of China's pharmaceutical industry in the past two years was much higher than the growth rate of sales revenues. The total profit of China's pharmaceutical industry in the first eleven months of 2007 reached CNY49.9 billion, jumping 51% year on year. In 2008, the industry continued maintaining the momentum of fast growth, and the total profit of the industry in the first five months of this year stood at CNY26 billion, 41.4% year on year, which is mainly attributed to government support and industry restructuring.
Due to the impact of many factors, including a price competition and market disorder, China's pharmaceutical chain industry was in trouble in the past four years. However, the industry had a turn for the better in 2007 after experiencing industry restructuring and gradually improved corporate operations in 2006. In 2007, net profit rate of China Top 100 pharmaceutical chain companies reached about 3%, higher than that in the previous year, and the growth rate of profit reached 56.2%, far higher than the growth rate of sales revenue.
Although we are optimistic about our forecast of potential market development, rapid expansion of pharmaceutical chain industry in large cities like Beijing, Shanghai, Guangzhou and Shenzhen has saturated the market in these large cities. Rising cost, price competition, new medical reform and other factors have made it increasingly difficult for medium- and small-sized drugstores to survive. It is increasingly clear that China should further restructure its pharmaceutical chain industry to raise industrial concentration degree, which is also a good opportunity for powerful companies to further strengthen their presence in the industry.
This report is based on the authoritative statistics of the National Bureau of Statistics, the Ministry of Health, the State Food and Drug Administration, the China Association of Pharmaceutical Commerce and the China Drugstore website, as well as information from annual financial reports and the websites of some key companies.
This title is also available in the following language
China Pharmaceutical Chain Industry Report, 2007-2008 (Chinese Version)
Customers who bought this item also bought
China Pharmaceutical Chain Industry Report, 2007-2008
China Pharmaceutical Chain Industry Report, 2007-2008
China Pharmaceutical Chain Industry Report, 2006
China Pharmaceutical Chain Industry Report 2006
In-Vitro Diagnostic Substance Manufacturing Industry in the U.S. and its Foreign Trade
Analyzing the Indian Retail Industry
Electronic Resistor Manufacturing Industry in the U.S. and its International Trade [Q3 2009 Edition]
Dental Equipment and Supplies Manufacturing Industry in the U.S. and its International Trade [Q3 2009 Edition]
|
|
|
|
